TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21168369

Group type: EXPERIMENTAL
Intervention: AS03(A) adjuvanted vaccine (3.75 μg of haemagglutinin)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Whole-virion vaccine (7.5 μg of haemagglutinin)
Number of subjects: 347
Study: 19298916

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 0.042 microg/kg/min; ANP group, n = 126
Number of subjects: 254

Group type: COMPARATOR
Intervention: Ringer solution alone; control group, n = 128
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 254
Study: 17551148

Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 22507

Group type: COMPARATOR
Intervention: Nonaspirin NSAID use
Number of subjects: 22507
Study: 15309603

Group type: EXPERIMENTAL
Intervention: Late summer months (August/September)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mid‐winter (January/February)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall UCa/Cr
Number of subjects: 65
Study: 11573662

Group type: EXPERIMENTAL
Intervention: LMA insertion (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laryngoscopy and tracheal intubation (n=20)
Number of subjects: 40
Study: 9183508

Group type: EXPERIMENTAL
Intervention: Binge-drinking events
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Estimates of the number of drinks required to impair driving
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Drinking location (outdoors or in a moving car/truck)
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Drinking occasions (specific to females)
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Drinking at someone else's house (specific to females)
Number of subjects: 1914
Study: 8188554

Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Follow-up dose based on trial-phase data
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 3499456

Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg body weight)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31978372

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional obesity treatment
Number of subjects: 161
Study: 30177465

Group type: EXPERIMENTAL
Intervention: FMOS lipid emulsion
Number of subjects: 67

Group type: COMPARATOR
Intervention: OO/SO lipid emulsion
Number of subjects: 67
Study: 28916667

Group type: EXPERIMENTAL
Intervention: IVMT (mechanical thrombectomy combined with intravenous thrombolysis)
Number of subjects: 402

Group type: COMPARATOR
Intervention: IVT (intravenous thrombolysis)
Number of subjects: 402
Study: 25635361

Group type: EXPERIMENTAL
Intervention: Patients without syndesmotic injury
Number of subjects: 242

Group type: COMPARATOR
Intervention: Patients with syndesmotic injury
Number of subjects: 242
Study: 23930638

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Monitoring without further treatment (Control)
Number of subjects: 62
Study: 22973331

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20201159

Group type: EXPERIMENTAL
Intervention: Holistic physiotherapy (customised programme including postisometric relaxation, active mobilisation, Kibler Fold mobilisation, Kinesiology Taping, Maigne's relaxing exercises)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electrotherapy and standard exercises for low back pain
Number of subjects: 60
Study: 17466494

Group type: EXPERIMENTAL
Intervention: Active transcranial magnetic stimulation (TMS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 99
Study: 15180756

Group type: EXPERIMENTAL
Intervention: Omalizumab (at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks for 12 months)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 312

Group type: COMPARATOR
Intervention: Best Standard Care (BSC) alone
Number of subjects: 312
Study: 11871867

Group type: EXPERIMENTAL
Intervention: Treatment options for pruritus in cancer patients; specific interventions not detailed.
Number of subjects: 0
Study: 9619655

Group type: EXPERIMENTAL
Intervention: Waterlow scores (all subjects)
Number of subjects: 9172

Group type: EXPERIMENTAL
Intervention: Braden scores (wheelchair users)
Number of subjects: 9172

Group type: EXPERIMENTAL
Intervention: Waterlow scores (wheelchair users)
Number of subjects: 9172
Study: 8302503

Group type: EXPERIMENTAL
Intervention: Weekly one hour exercise classes supervised by a physiotherapist
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular rest home activities without physiotherapy input
Number of subjects: 34
Study: 2720716

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 13
Study: 30113209

Group type: EXPERIMENTAL
Intervention: Oral sensorimotor intervention (15-minute program: stroking peri‐oral structures for 5 minutes, tongue exercises for 5 minutes, non‐nutritive sucking for 5 minutes, administered once daily for 10 days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral sensorimotor intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (sham intervention for the same duration)
Number of subjects: 31
Study: 28043015

Group type: EXPERIMENTAL
Intervention: Unfolding nursing cases
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual nursing cases
Number of subjects: 122
Study: 25925026

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.241%
Number of subjects: 0
Study: 23953766

Group type: EXPERIMENTAL
Intervention: Vesicoamniotic shunt
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study: 21600388

Group type: EXPERIMENTAL
Intervention: Oral B(12) 1000 μg daily for 90 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: IM B(12) 1000 μg in 9 injections over 3 months
Number of subjects: 50
Study: 19457640

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FS) 120mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sodium iron ethylenediaminetetra-acetic acid (EDTA) 5mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dehydrated cell fraction (DCF) high-dose 120mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dehydrated cell fraction (DCF) low-dose 5mg
Number of subjects: 13
Study: 16698309

Group type: EXPERIMENTAL
Intervention: Regimen 1 (OPTI-FREE RepleniSH MPDS, Alcon Laboratories Inc.)
Number of subjects: 362
Study: 15180835

Group type: EXPERIMENTAL
Intervention: Indirect diode laser photocoagulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 36
Study: 11207509

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg on-demand therapy
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo on-demand therapy
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg and Placebo
Number of subjects: 342
Study: 9421340

Group type: EXPERIMENTAL
Intervention: Training course for index group (n = 12 doctors)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group 1 (n = 12 doctors)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group 2 (n = 4 doctors)
Number of subjects: 28
Study: 2019804

Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gauze swabs
Number of subjects: 99
Study: 7047575

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day)
Number of subjects: 51
Study: 30266677

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (ID-AraC) plus G-CSF
Number of subjects: 90

Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 90
Study: 26738812

Group type: EXPERIMENTAL
Intervention: PF-03049423 6 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23340738

Group type: EXPERIMENTAL
Intervention: Bendamustine 100 mg/m² on days 1 and 2 of a 4-week cycle
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fludarabine 25 mg/m² on days 1 to 5 every 4 weeks
Number of subjects: 92
Study: 21320116

Group type: EXPERIMENTAL
Intervention: Single seizure only
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Early remission
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Late remission
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Relapse after seizure-free period
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Persistent seizures
Number of subjects: 253
Study: 19229667

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenously weekly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Interferon-alpha (3 million units subcutaneously three times weekly, escalating to 18 MU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Temsirolimus vs Interferon-alpha
Number of subjects: 100
Study: 16735934

Group type: EXPERIMENTAL
Intervention: lasofoxifene 0.25 mg/day
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: lasofoxifene 1.0 mg/day
Number of subjects: 410

Group type: COMPARATOR
Intervention: raloxifene 60 mg/day
Number of subjects: 410

Group type: COMPARATOR
Intervention: lasofoxifene and raloxifene
Number of subjects: 410
Study: 15509758

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the somatosensory cortex contralateral to the hand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 11221551

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9846844

Group type: EXPERIMENTAL
Intervention: Sibutramine (30 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7919465

Group type: EXPERIMENTAL
Intervention: Natural IFN beta (Frone) administered by intramuscular injection at a dosage of 5 Million Units (MU)/m2 three times weekly for six months
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Natural IFN beta (Frone) administered by intramuscular injection
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 65
Study: 3041817

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus piperacillin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mezlocillin plus tobramycin
Number of subjects: 30
Study: 29463211

Group type: EXPERIMENTAL
Intervention: Repositioning every 2 hours
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Repositioning every 3 hours
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Repositioning every 4 hours
Number of subjects: 951
Study: 26869500

Group type: EXPERIMENTAL
Intervention: Traditional mail (pen and paper)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 73

Group type: COMPARATOR
Intervention: E-mail
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Traditional mail and telephone
Number of subjects: 73
Study: 25783647

Group type: EXPERIMENTAL
Intervention: SWETZ
Number of subjects: 164

Group type: COMPARATOR
Intervention: LLETZ-cone
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 164
Study: 23027701

Group type: EXPERIMENTAL
Intervention: Mehran risk score - high risk (11-15)
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Mehran risk score - very high risk (≥16)
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Mehran risk score - moderate risk (6-10)
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Contrast-induced nephropathy (CIN)
Number of subjects: 1041
Study: 21345600

Group type: EXPERIMENTAL
Intervention: 3.6% garlic treatment group
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0% garlic treatment group
Number of subjects: 31

Group type: COMPARATOR
Intervention: 1.8% garlic treatment group
Number of subjects: 31
Study: 17617188

Group type: EXPERIMENTAL
Intervention: NovaSure (bipolar radio-frequency ablation)
Number of subjects: 126

Group type: COMPARATOR
Intervention: ThermaChoice (balloon ablation)
Number of subjects: 126
Study: 16339606

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (2.5 mg/kg twice daily)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Fluconazole oral solution or capsules (400 mg daily)
Number of subjects: 494
Study: 12580982

Group type: EXPERIMENTAL
Intervention: nelfinavir/ritonavir 2,000/200 mg with a full breakfast
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: nelfinavir/ritonavir 2,000/400 mg with a full breakfast
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: nelfinavir/ritonavir 2,500/200 mg with a full breakfast
Number of subjects: 27

Group type: COMPARATOR
Intervention: nelfinavir/ritonavir with a light breakfast
Number of subjects: 27
Study: 10951826

Group type: EXPERIMENTAL
Intervention: Carvedilol (initial dose 12.5 mg, increased weekly to 75 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8733066

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study: 7908570

Group type: EXPERIMENTAL
Intervention: Ethamsylate 12.5 mg/kg intravenously within an hour of delivery, followed by doses at six-hourly intervals for four days (total dose 200 mg/kg)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Normal saline 0.1 mL/kg intravenously
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Ethamsylate 12.5 mg/kg intravenously
Number of subjects: 171
Study: 3773677

Group type: EXPERIMENTAL
Intervention: Inclined terrain running (IP) 4 times/wk for 35 min/session at 65 to 85% of maximal aerobic power for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Horizontal protocol (HP)
Number of subjects: 22
Study: 29534382

Group type: EXPERIMENTAL
Intervention: Ultrasound guided quadratus lumborum block with 30 ml 0.33% ropivacaine
Number of subjects: 60
Study: 27557406

Group type: EXPERIMENTAL
Intervention: Jump training group (JG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Jump training group plus haltere type handheld loading (LJG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 63
Study: 24737045

Group type: EXPERIMENTAL
Intervention: Different-system condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Same-system condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different-system condition (replicated in Experiment 2)
Number of subjects: 0
Study: 23760393

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (16 sessions)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Escitalopram oxalate (10-20 mg/d)
Number of subjects: 65
Study: 20220589

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 18171292

Group type: EXPERIMENTAL
Intervention: TDF+PI/r
Number of subjects: 146

Group type: COMPARATOR
Intervention: TDF+NNRTI
Number of subjects: 146

Group type: COMPARATOR
Intervention: non-TDF-containing regimen
Number of subjects: 146
Study: 16921080

Group type: EXPERIMENTAL
Intervention: Dedicated A&E psychiatric nurse service (4 experienced community psychiatric nurses)
Number of subjects: 100
Study: 12746632

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10816183

Group type: EXPERIMENTAL
Intervention: Nefazodone (maximal dose, 600 mg per day)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Combined treatment (Nefazodone + Cognitive behavioral-analysis system of psychotherapy)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral-analysis system of psychotherapy
Number of subjects: 681
Study: 8643759

Group type: EXPERIMENTAL
Intervention: LLPDD subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 30
Study: 1574663

Group type: EXPERIMENTAL
Intervention: Visual model performing an underhand modified softball pitch with verbal performance cues added at the second, third, or fourth trial block.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Visual model performing an underhand modified softball pitch without verbal performance cues.
Number of subjects: 36
Study: 6148473

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31589587

Group type: EXPERIMENTAL
Intervention: SRP+aPDT (using a low-power laser application Photon Lase III with operational parameters of 660 nm and 100 mW for 15 sec)
Number of subjects: 54

Group type: COMPARATOR
Intervention: SRP (control group)
Number of subjects: 54
Study: 29300289

Group type: EXPERIMENTAL
Intervention: Clean stoma catheterization
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Urine dripping from the stoma
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clean urostomy pouch
Number of subjects: 27
Study: 27631562

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CE/BZA
Number of subjects: 60
Study: 24722494

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study: 22737979

Group type: EXPERIMENTAL
Intervention: Best practices primary care plus home-based occupational therapy (24 sessions over 2 years)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Best practices primary care
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Best practices primary care plus home-based occupational therapy
Number of subjects: 180
Study: 20736456

Group type: EXPERIMENTAL
Intervention: Immunoblastic (IB) morphology
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Immunohistochemical markers (CD5, CD10, BCL2, BCL6, HLA-DR, IRF4/MUM1, Ki-67)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Hans algorithm using CD10, BCL6, and IRF4/MUM1
Number of subjects: 949
Study: 18539675

Group type: EXPERIMENTAL
Intervention: Lengthening of the flexor hallucis longus and flexor digitorum longus tendons
Number of subjects: 13

Group type: COMPARATOR
Intervention: Simple decompression
Number of subjects: 13
Study: 15989908

Group type: EXPERIMENTAL
Intervention: Elective primary stent (n = 124)
Number of subjects: 246
Study: 12460397

Group type: EXPERIMENTAL
Intervention: Standardized behavioural intervention implemented in 12 communities (arms A and B) through community-based education, meetings, and information leaflets.
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Improved STD management through government and private health units (arm B).
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Routine government health services (arm C).
Number of subjects: 15000
Study: 9845803

Group type: EXPERIMENTAL
Intervention: ITF 296 (oral solution)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ITF 296 (immediate-release tablet)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ITF 296 (intravenous infusion)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ITF 296 (oral administration)
Number of subjects: 11
Study: 7482015

Group type: EXPERIMENTAL
Intervention: Back pain care episodes
Number of subjects: 3105

Group type: EXPERIMENTAL
Intervention: Sociodemographic and health status variables
Number of subjects: 3105
Study: 2158869

Group type: EXPERIMENTAL
Intervention: Insulin injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 6
Study: 338412

Group type: EXPERIMENTAL
Intervention: Trasylol administered before and after ERCP
Number of subjects: 61
Study: 31953483

Group type: EXPERIMENTAL
Intervention: TP-fusion
Number of subjects: 77

Group type: COMPARATOR
Intervention: TR-fusion
Number of subjects: 77
Study: 30958014

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Combination treatment (COMB)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 318
Study: 28467293

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg intravenous treatment (concurrent cohort)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination (pre-belimumab cohort)
Number of subjects: 79
Study: 26077267

Group type: EXPERIMENTAL
Intervention: Self-monitoring of oral anticoagulation therapy (OAT)
Number of subjects: 296
Study: 23632782

Group type: EXPERIMENTAL
Intervention: Multi-level drill guide template for pedicle screw placement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fluoroscopy-supervised free-hand technique
Number of subjects: 20
Study: 21768322

Group type: EXPERIMENTAL
Intervention: Very preterm children
Number of subjects: 363

Group type: COMPARATOR
Intervention: Term children
Number of subjects: 363
Study: 19630546

Group type: EXPERIMENTAL
Intervention: Enhanced Treatment (ET) walking intervention
Number of subjects: 278

Group type: COMPARATOR
Intervention: Minimal Treatment (MT) walking intervention
Number of subjects: 278
Study: 16991061

Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 115

Group type: COMPARATOR
Intervention: Total knee replacement
Number of subjects: 115
Study: 15499150

Group type: EXPERIMENTAL
Intervention: PIPP (Premature Infant Pain Profile)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CRIES (Crying, Requires oxygen, Increased vital signs, Expression, Sleepless)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 51
Study: 10690871

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg/day for 2 months, then 200 microg/day thereafter
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 microg/day for 2 months, then 400 microg/day thereafter
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cromone (CROM)
Number of subjects: 75
Study: 10179578

Group type: EXPERIMENTAL
Intervention: Neural network analysis of biochemical markers (myoglobin, CK-MB, troponin-T) for early diagnosis/exclusion of AMI.
Number of subjects: 88